MPS1 kinase as a potential therapeutic target in medulloblastoma
Medulloblastoma is the most common type of malignant brain tumor that affects children. Although recent advances in chemotherapy and radiation have improved outcomes, high-risk patients perform poorly with significant morbidity. Gene expression profiling has revealed that monopolar spindle 1 (MPS1)...
Gespeichert in:
| Veröffentlicht in: | Oncology reports 2016-11, Vol.36 (5), p.2633-2640 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2640 |
|---|---|
| container_issue | 5 |
| container_start_page | 2633 |
| container_title | Oncology reports |
| container_volume | 36 |
| creator | Alimova, Irina Ng, June Harris, Peter Birks, Diane Donson, Andrew Taylor, Michael D Foreman, Nicholas K Venkataraman, Sujatha Vibhakar, Rajeev |
| description | Medulloblastoma is the most common type of malignant brain tumor that affects children. Although recent advances in chemotherapy and radiation have improved outcomes, high-risk patients perform poorly with significant morbidity. Gene expression profiling has revealed that monopolar spindle 1 (MPS1) (TTK1) is highly expressed in medulloblastoma patient samples compared to that noted in normal cerebellum. MPS1 is a key regulator of the spindle assembly checkpoint (SAC), a mitotic mechanism specifically required for proper chromosomal alignment and segregation. The SAC can be activated in aneuploid cancer cells and MPS1 is overexpressed in many types of cancers. A previous study has demonstrated the effectiveness of inhibiting MPS1 with small-molecule inhibitors, but the role of MPS1 in medulloblastoma is unknown. In the present study, we demonstrated that MPS1 inhibition by shRNA or with a small-molecule drug, NMS-P715, resulted in decreased cell growth, inhibition of clonogenic potential and induction of apoptosis in cells belonging to both the Shh and group 3 medulloblastoma genomic signature. These findings highlight MPS1 as a rational therapeutic target for medulloblastoma. |
| doi_str_mv | 10.3892/or.2016.5085 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5055207</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A473383769</galeid><sourcerecordid>A473383769</sourcerecordid><originalsourceid>FETCH-LOGICAL-c568t-f02492cb94d3123f3ac4e8fa71eb57750b787053d897faaf527862a28c11645b3</originalsourceid><addsrcrecordid>eNpdkUFrFTEUhYNYbK3uXMuAIC6cZ5I7mWQ2xVLUFioKKrgLdzKZ91LzJmOSEfz3zaO1r3WVC_k499xzCHnB6ApUx9-FuOKUtStBlXhEjpjsWM0bYI_LTDmrAcTPQ_I0pStKuaRt94QcctkCUApH5P3nr99Y9ctNmGyFqcJqDtlO2aGv8sZGnO2SnakyxrXNlZuqrR0W70PvMeWwxWfkYESf7PPb95j8-Pjh-9l5ffnl08XZ6WVtRKtyPVLedNz0XTMA4zACmsaqESWzvZBS0F4qSQUMqpMj4ii4VC1HrgxjbSN6OCYnN7rz0hcLpniM6PUc3RbjXx3Q6Yc_k9vodfijBRWCU1kE3twKxPB7sSnrrUvGeo-TDUvSTIFooClZFvTVf-hVWOJUztOsA95KVizvqTV6q900hrLX7ET1aSMBFMi2K9Tre9TGos-bFHwJNUzpIfj2BjQxpBTteHcbo3rXtA5R75rWu6YL_vJ-Hnfwv2r3i9OM0-CGkPZhxRramoqaFxauAcXzrbg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932671577</pqid></control><display><type>article</type><title>MPS1 kinase as a potential therapeutic target in medulloblastoma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Alimova, Irina ; Ng, June ; Harris, Peter ; Birks, Diane ; Donson, Andrew ; Taylor, Michael D ; Foreman, Nicholas K ; Venkataraman, Sujatha ; Vibhakar, Rajeev</creator><creatorcontrib>Alimova, Irina ; Ng, June ; Harris, Peter ; Birks, Diane ; Donson, Andrew ; Taylor, Michael D ; Foreman, Nicholas K ; Venkataraman, Sujatha ; Vibhakar, Rajeev</creatorcontrib><description>Medulloblastoma is the most common type of malignant brain tumor that affects children. Although recent advances in chemotherapy and radiation have improved outcomes, high-risk patients perform poorly with significant morbidity. Gene expression profiling has revealed that monopolar spindle 1 (MPS1) (TTK1) is highly expressed in medulloblastoma patient samples compared to that noted in normal cerebellum. MPS1 is a key regulator of the spindle assembly checkpoint (SAC), a mitotic mechanism specifically required for proper chromosomal alignment and segregation. The SAC can be activated in aneuploid cancer cells and MPS1 is overexpressed in many types of cancers. A previous study has demonstrated the effectiveness of inhibiting MPS1 with small-molecule inhibitors, but the role of MPS1 in medulloblastoma is unknown. In the present study, we demonstrated that MPS1 inhibition by shRNA or with a small-molecule drug, NMS-P715, resulted in decreased cell growth, inhibition of clonogenic potential and induction of apoptosis in cells belonging to both the Shh and group 3 medulloblastoma genomic signature. These findings highlight MPS1 as a rational therapeutic target for medulloblastoma.</description><identifier>ISSN: 1021-335X</identifier><identifier>EISSN: 1791-2431</identifier><identifier>DOI: 10.3892/or.2016.5085</identifier><identifier>PMID: 27633003</identifier><language>eng</language><publisher>Greece: D.A. Spandidos</publisher><subject>Apoptosis ; Apoptosis - drug effects ; Brain cancer ; Cancer therapies ; Care and treatment ; Cell cycle ; Cell Cycle - drug effects ; Cell Cycle Proteins - antagonists & inhibitors ; Cell Cycle Proteins - biosynthesis ; Cell Cycle Proteins - genetics ; Cell growth ; Cell Proliferation - drug effects ; Diagnosis ; Gene expression ; Gene Expression Regulation, Neoplastic - drug effects ; Genetic aspects ; Health aspects ; HeLa Cells ; Humans ; Innovations ; kinase ; Kinases ; M Phase Cell Cycle Checkpoints - drug effects ; Medical research ; Medulloblastoma ; Medulloblastoma - drug therapy ; Medulloblastoma - genetics ; Medulloblastoma - pathology ; mitosis ; Mitosis - genetics ; Molecular Targeted Therapy ; MPS1 ; NMS-P715 ; Phosphotransferases ; Protein-Serine-Threonine Kinases - antagonists & inhibitors ; Protein-Serine-Threonine Kinases - biosynthesis ; Protein-Serine-Threonine Kinases - genetics ; Protein-Tyrosine Kinases - antagonists & inhibitors ; Protein-Tyrosine Kinases - biosynthesis ; Protein-Tyrosine Kinases - genetics ; Pyrazoles - administration & dosage ; Quinazolines - administration & dosage</subject><ispartof>Oncology reports, 2016-11, Vol.36 (5), p.2633-2640</ispartof><rights>Copyright © 2016, Spandidos Publications</rights><rights>COPYRIGHT 2016 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2016</rights><rights>Copyright © 2016, Spandidos Publications 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c568t-f02492cb94d3123f3ac4e8fa71eb57750b787053d897faaf527862a28c11645b3</citedby><cites>FETCH-LOGICAL-c568t-f02492cb94d3123f3ac4e8fa71eb57750b787053d897faaf527862a28c11645b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27633003$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alimova, Irina</creatorcontrib><creatorcontrib>Ng, June</creatorcontrib><creatorcontrib>Harris, Peter</creatorcontrib><creatorcontrib>Birks, Diane</creatorcontrib><creatorcontrib>Donson, Andrew</creatorcontrib><creatorcontrib>Taylor, Michael D</creatorcontrib><creatorcontrib>Foreman, Nicholas K</creatorcontrib><creatorcontrib>Venkataraman, Sujatha</creatorcontrib><creatorcontrib>Vibhakar, Rajeev</creatorcontrib><title>MPS1 kinase as a potential therapeutic target in medulloblastoma</title><title>Oncology reports</title><addtitle>Oncol Rep</addtitle><description>Medulloblastoma is the most common type of malignant brain tumor that affects children. Although recent advances in chemotherapy and radiation have improved outcomes, high-risk patients perform poorly with significant morbidity. Gene expression profiling has revealed that monopolar spindle 1 (MPS1) (TTK1) is highly expressed in medulloblastoma patient samples compared to that noted in normal cerebellum. MPS1 is a key regulator of the spindle assembly checkpoint (SAC), a mitotic mechanism specifically required for proper chromosomal alignment and segregation. The SAC can be activated in aneuploid cancer cells and MPS1 is overexpressed in many types of cancers. A previous study has demonstrated the effectiveness of inhibiting MPS1 with small-molecule inhibitors, but the role of MPS1 in medulloblastoma is unknown. In the present study, we demonstrated that MPS1 inhibition by shRNA or with a small-molecule drug, NMS-P715, resulted in decreased cell growth, inhibition of clonogenic potential and induction of apoptosis in cells belonging to both the Shh and group 3 medulloblastoma genomic signature. These findings highlight MPS1 as a rational therapeutic target for medulloblastoma.</description><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Brain cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Cell cycle</subject><subject>Cell Cycle - drug effects</subject><subject>Cell Cycle Proteins - antagonists & inhibitors</subject><subject>Cell Cycle Proteins - biosynthesis</subject><subject>Cell Cycle Proteins - genetics</subject><subject>Cell growth</subject><subject>Cell Proliferation - drug effects</subject><subject>Diagnosis</subject><subject>Gene expression</subject><subject>Gene Expression Regulation, Neoplastic - drug effects</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>HeLa Cells</subject><subject>Humans</subject><subject>Innovations</subject><subject>kinase</subject><subject>Kinases</subject><subject>M Phase Cell Cycle Checkpoints - drug effects</subject><subject>Medical research</subject><subject>Medulloblastoma</subject><subject>Medulloblastoma - drug therapy</subject><subject>Medulloblastoma - genetics</subject><subject>Medulloblastoma - pathology</subject><subject>mitosis</subject><subject>Mitosis - genetics</subject><subject>Molecular Targeted Therapy</subject><subject>MPS1</subject><subject>NMS-P715</subject><subject>Phosphotransferases</subject><subject>Protein-Serine-Threonine Kinases - antagonists & inhibitors</subject><subject>Protein-Serine-Threonine Kinases - biosynthesis</subject><subject>Protein-Serine-Threonine Kinases - genetics</subject><subject>Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Protein-Tyrosine Kinases - biosynthesis</subject><subject>Protein-Tyrosine Kinases - genetics</subject><subject>Pyrazoles - administration & dosage</subject><subject>Quinazolines - administration & dosage</subject><issn>1021-335X</issn><issn>1791-2431</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkUFrFTEUhYNYbK3uXMuAIC6cZ5I7mWQ2xVLUFioKKrgLdzKZ91LzJmOSEfz3zaO1r3WVC_k499xzCHnB6ApUx9-FuOKUtStBlXhEjpjsWM0bYI_LTDmrAcTPQ_I0pStKuaRt94QcctkCUApH5P3nr99Y9ctNmGyFqcJqDtlO2aGv8sZGnO2SnakyxrXNlZuqrR0W70PvMeWwxWfkYESf7PPb95j8-Pjh-9l5ffnl08XZ6WVtRKtyPVLedNz0XTMA4zACmsaqESWzvZBS0F4qSQUMqpMj4ii4VC1HrgxjbSN6OCYnN7rz0hcLpniM6PUc3RbjXx3Q6Yc_k9vodfijBRWCU1kE3twKxPB7sSnrrUvGeo-TDUvSTIFooClZFvTVf-hVWOJUztOsA95KVizvqTV6q900hrLX7ET1aSMBFMi2K9Tre9TGos-bFHwJNUzpIfj2BjQxpBTteHcbo3rXtA5R75rWu6YL_vJ-Hnfwv2r3i9OM0-CGkPZhxRramoqaFxauAcXzrbg</recordid><startdate>20161101</startdate><enddate>20161101</enddate><creator>Alimova, Irina</creator><creator>Ng, June</creator><creator>Harris, Peter</creator><creator>Birks, Diane</creator><creator>Donson, Andrew</creator><creator>Taylor, Michael D</creator><creator>Foreman, Nicholas K</creator><creator>Venkataraman, Sujatha</creator><creator>Vibhakar, Rajeev</creator><general>D.A. Spandidos</general><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20161101</creationdate><title>MPS1 kinase as a potential therapeutic target in medulloblastoma</title><author>Alimova, Irina ; Ng, June ; Harris, Peter ; Birks, Diane ; Donson, Andrew ; Taylor, Michael D ; Foreman, Nicholas K ; Venkataraman, Sujatha ; Vibhakar, Rajeev</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c568t-f02492cb94d3123f3ac4e8fa71eb57750b787053d897faaf527862a28c11645b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Brain cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Cell cycle</topic><topic>Cell Cycle - drug effects</topic><topic>Cell Cycle Proteins - antagonists & inhibitors</topic><topic>Cell Cycle Proteins - biosynthesis</topic><topic>Cell Cycle Proteins - genetics</topic><topic>Cell growth</topic><topic>Cell Proliferation - drug effects</topic><topic>Diagnosis</topic><topic>Gene expression</topic><topic>Gene Expression Regulation, Neoplastic - drug effects</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>HeLa Cells</topic><topic>Humans</topic><topic>Innovations</topic><topic>kinase</topic><topic>Kinases</topic><topic>M Phase Cell Cycle Checkpoints - drug effects</topic><topic>Medical research</topic><topic>Medulloblastoma</topic><topic>Medulloblastoma - drug therapy</topic><topic>Medulloblastoma - genetics</topic><topic>Medulloblastoma - pathology</topic><topic>mitosis</topic><topic>Mitosis - genetics</topic><topic>Molecular Targeted Therapy</topic><topic>MPS1</topic><topic>NMS-P715</topic><topic>Phosphotransferases</topic><topic>Protein-Serine-Threonine Kinases - antagonists & inhibitors</topic><topic>Protein-Serine-Threonine Kinases - biosynthesis</topic><topic>Protein-Serine-Threonine Kinases - genetics</topic><topic>Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Protein-Tyrosine Kinases - biosynthesis</topic><topic>Protein-Tyrosine Kinases - genetics</topic><topic>Pyrazoles - administration & dosage</topic><topic>Quinazolines - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alimova, Irina</creatorcontrib><creatorcontrib>Ng, June</creatorcontrib><creatorcontrib>Harris, Peter</creatorcontrib><creatorcontrib>Birks, Diane</creatorcontrib><creatorcontrib>Donson, Andrew</creatorcontrib><creatorcontrib>Taylor, Michael D</creatorcontrib><creatorcontrib>Foreman, Nicholas K</creatorcontrib><creatorcontrib>Venkataraman, Sujatha</creatorcontrib><creatorcontrib>Vibhakar, Rajeev</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alimova, Irina</au><au>Ng, June</au><au>Harris, Peter</au><au>Birks, Diane</au><au>Donson, Andrew</au><au>Taylor, Michael D</au><au>Foreman, Nicholas K</au><au>Venkataraman, Sujatha</au><au>Vibhakar, Rajeev</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MPS1 kinase as a potential therapeutic target in medulloblastoma</atitle><jtitle>Oncology reports</jtitle><addtitle>Oncol Rep</addtitle><date>2016-11-01</date><risdate>2016</risdate><volume>36</volume><issue>5</issue><spage>2633</spage><epage>2640</epage><pages>2633-2640</pages><issn>1021-335X</issn><eissn>1791-2431</eissn><abstract>Medulloblastoma is the most common type of malignant brain tumor that affects children. Although recent advances in chemotherapy and radiation have improved outcomes, high-risk patients perform poorly with significant morbidity. Gene expression profiling has revealed that monopolar spindle 1 (MPS1) (TTK1) is highly expressed in medulloblastoma patient samples compared to that noted in normal cerebellum. MPS1 is a key regulator of the spindle assembly checkpoint (SAC), a mitotic mechanism specifically required for proper chromosomal alignment and segregation. The SAC can be activated in aneuploid cancer cells and MPS1 is overexpressed in many types of cancers. A previous study has demonstrated the effectiveness of inhibiting MPS1 with small-molecule inhibitors, but the role of MPS1 in medulloblastoma is unknown. In the present study, we demonstrated that MPS1 inhibition by shRNA or with a small-molecule drug, NMS-P715, resulted in decreased cell growth, inhibition of clonogenic potential and induction of apoptosis in cells belonging to both the Shh and group 3 medulloblastoma genomic signature. These findings highlight MPS1 as a rational therapeutic target for medulloblastoma.</abstract><cop>Greece</cop><pub>D.A. Spandidos</pub><pmid>27633003</pmid><doi>10.3892/or.2016.5085</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1021-335X |
| ispartof | Oncology reports, 2016-11, Vol.36 (5), p.2633-2640 |
| issn | 1021-335X 1791-2431 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5055207 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Apoptosis Apoptosis - drug effects Brain cancer Cancer therapies Care and treatment Cell cycle Cell Cycle - drug effects Cell Cycle Proteins - antagonists & inhibitors Cell Cycle Proteins - biosynthesis Cell Cycle Proteins - genetics Cell growth Cell Proliferation - drug effects Diagnosis Gene expression Gene Expression Regulation, Neoplastic - drug effects Genetic aspects Health aspects HeLa Cells Humans Innovations kinase Kinases M Phase Cell Cycle Checkpoints - drug effects Medical research Medulloblastoma Medulloblastoma - drug therapy Medulloblastoma - genetics Medulloblastoma - pathology mitosis Mitosis - genetics Molecular Targeted Therapy MPS1 NMS-P715 Phosphotransferases Protein-Serine-Threonine Kinases - antagonists & inhibitors Protein-Serine-Threonine Kinases - biosynthesis Protein-Serine-Threonine Kinases - genetics Protein-Tyrosine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - biosynthesis Protein-Tyrosine Kinases - genetics Pyrazoles - administration & dosage Quinazolines - administration & dosage |
| title | MPS1 kinase as a potential therapeutic target in medulloblastoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T06%3A37%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MPS1%20kinase%20as%20a%20potential%20therapeutic%20target%20in%20medulloblastoma&rft.jtitle=Oncology%20reports&rft.au=Alimova,%20Irina&rft.date=2016-11-01&rft.volume=36&rft.issue=5&rft.spage=2633&rft.epage=2640&rft.pages=2633-2640&rft.issn=1021-335X&rft.eissn=1791-2431&rft_id=info:doi/10.3892/or.2016.5085&rft_dat=%3Cgale_pubme%3EA473383769%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932671577&rft_id=info:pmid/27633003&rft_galeid=A473383769&rfr_iscdi=true |